Skip to main content

A 52-week, double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib, 150 mg twice daily, in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Corporation

Start Date

April 19, 2017

End Date

March 31, 2020
 

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Corporation

Start Date

April 19, 2017

End Date

March 31, 2020